Fitch affirms Bristol-Myers

Fitch Ratings said it affirmed Bristol-Myers Squibb Co.'s A+ issuer default rating, senior unsecured debt rating and bank loan and F1 commercial paper rating and removed them from Rating Watch negative, where they were placed on Aug. 8, 2006.

The outlook is stable.

The agency said the affirmation reflects that the significant uncertainty surrounding intellectual property protection of Bristol-Myers' top-selling product, Plavix (clopidogrel), has been mitigated in cooperation with its joint venture partner, sanofi-aventis SA. During the second quarter, the companies successfully defended the clopidogrel composition-of-matter patent in the U.S. against Apotex Corp.'s legal challenge to invalidate the patent.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.